Alzheimer’s disease has been one of the toughest disorders for drugmakers to tackle, with multiple trial failures year after year. Companies have exhausted resources as they examined different pathways in what have mostly been futile attempts to develop a therapeutic to halt or delay the onset of this devastating neurodegenerative disease.
NeuroNascent Takes New Path for Alzheimer’s Treatment
